Skip to main content

Bioxytran, Inc

BIXT
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001445815

No open-market purchases or sales by Bioxytran, Inc insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Bioxytran, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Bioxytran, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Bioxytran, Inc
NameTitleLast reported holdingLast filingFilings, past year
Hoberman Alan MDirector210,000Nov 18, 20251
Milanova RadkaDirector203,688Nov 18, 20251
Conaway Dale HDirector379,177Nov 18, 20251
Utter AndersDirector372,580Nov 18, 20251
Platt DavidCEO20,038,903Nov 18, 20251
Soderquist OlaCFO500,000Nov 18, 20251
Sheikh MichaelCCO8,214,720Nov 18, 20251
Chen-Walden HanaDirector367,800Oct 10, 20230
Offer BinderOther: No longer 10% owner–Jul 6, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2025 (view filing)4:15 PM ETNov 18Same dayHoberman Alan MDirectorPPurchasecommon+210.0K$0.60+$126.0KNew position210.0K after
Aug 20, 2024 (view filing)5:10 PM ETAug 155 daysLatePlatt DavidCEOPPurchasecommon+1.59M$0.124+$197.5K+7.9%21.7M after